Biogen Idec Inc. (BIIB) and Biovitrum AB (BIOVY, BVT.SK) said they will move ahead in testing their protein treatment for a type of hemophilia after it was well tolerated in an earlier study.

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Saliva in hemophilia A patients contains vesicles with extrinsic tenase complexes, which trigger rapid blood coagulation, explaining why mucosal bleeding is rare in these patients.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

Saliva activates coagulation in persons with hemophilia A. ScienceDaily. Retrieved February 1, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250114125253.htm Medical University of Vienna.

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...